Calidi Biotherapeutics Inc [AMEX: CLDI] stock went on an upward path that rose over 38.49% on Monday, amounting to a one-week price increase of more than 59.07%.
Over the last 12 months, CLDI stock dropped by -86.88%. The one-year Calidi Biotherapeutics Inc stock forecast points to a potential upside of 83.2. The average equity rating for CLDI stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $27.21 million, with 93.11 million shares outstanding and 16.88 million shares in the current float. Compared to the average trading volume of 1.91M shares, CLDI stock reached a trading volume of 8853455 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Calidi Biotherapeutics Inc [CLDI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLDI shares is $6.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLDI stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Calidi Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 22, 2023. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on October 09, 2023, representing the official price target for Calidi Biotherapeutics Inc stock.
CLDI Stock Performance Analysis:
Calidi Biotherapeutics Inc [CLDI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 59.07. With this latest performance, CLDI shares dropped by -8.70% in over the last four-week period, additionally sinking by -37.13% over the last 6 months – not to mention a drop of -86.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLDI stock in for the last two-week period is set at 51.55, with the RSI for the last a single of trading hit 62.17, and the three-weeks RSI is set at 47.50 for Calidi Biotherapeutics Inc [CLDI]. The present Moving Average for the last 50 days of trading for this stock 1.4432, while it was recorded at 0.7470 for the last single week of trading, and 1.5951 for the last 200 days.
Insight into Calidi Biotherapeutics Inc Fundamentals:
Calidi Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.19 and a Current Ratio set at 0.19.
Calidi Biotherapeutics Inc [CLDI] Institutonal Ownership Details
There are presently around $2.71%, or 3.31%% of CLDI stock, in the hands of institutional investors. The top three institutional holders of CLDI stocks are: RED WAVE INVESTMENTS LLC with ownership of 0.62 million shares, which is approximately 1.1723%. CPR INVESTMENTS INC., holding 0.56 million shares of the stock with an approximate value of $$0.11 million in CLDI stocks shares; and CPR INVESTMENTS INC., currently with $$52694.0 in CLDI stock with ownership which is approximately 0.4945%.
